Skip to main content
. 2024 May 14;7(5):e2411076. doi: 10.1001/jamanetworkopen.2024.11076

Table 5. COVID-19 Pandemic–Related Disruptions Associated With Hepatocellular Carcinoma Surveillance.

COVID-19 pandemic–related disruptions Respondents, No. (%)a P value
Internal medicine or family medicine Gastroenterology and hepatology
During the pandemic, my patients with cirrhosis often missed their regularly scheduled appointments (n = 182)
Strongly agree or agree 116 (84.7) 41 (91.1) .28
Strongly disagree or disagree 21 (15.3) 4 (8.9)
Patients with cirrhosis in my clinic were able to transition to telehealth visits without difficulty (n = 178)
Strongly agree or agree 76 (57.1) 29 (64.4) .39
Strongly disagree or disagree 57 (42.9) 16 (35.6)
Liver cancer screening was delayed or postponed during the pandemic due to limitations of in-person visits (n = 181)
Strongly agree or agree 113 (83.7) 38 (82.6) .86
Strongly disagree or disagree 22 (16.3) 8 (17.4)
I have an effective mechanism to keep track of patients with cirrhosis who have missed their liver cancer screening during the pandemic to make sure they are rescheduled (n = 180)
Strongly agree or agree 12 (8.9) 10 (22.2) .02
Strongly disagree or disagree 123 (91.1) 35 (77.8)
Currently, all my patients who need liver cancer screening can get their testing scheduled without delays (n = 181)
Strongly agree or agree 62 (45.6) 27 (60.0) .09
Strongly disagree or disagree 74 (54.4) 18 (40.0)
Currently, all the pandemic related delays or barriers in scheduling liver cancer screening have been completely resolved in my practice setting (n = 180)
Strongly agree or agree 68 (50.4) 31 (68.9) .03
Strongly disagree or disagree 67 (49.6) 14 (31.1)
a

Not all respondents answered all questions. Calculation of proportions were based on the total number of clinicians who answered each question. The number in parentheses in the first column indicates the total number of respondents for each category.